Owner Scorecard


← All companies ← WSR Manual WT → ← WRBY Medical Devices & Equipment XRAY →

WST, West Pharmaceutical

Medical Devices & Equipment capital-intensive

We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products.

Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions.

Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect.

Latest annual: FY2025 10-K
WST · West Pharmaceutical
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$3.1B
+6.3% YoY · 7% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue $3.2B 5-yr avg $2.9B
Gross margin 36% 5-yr avg 38%
Operating margin 20.3% 5-yr avg 22.7%
ROIC 19% 5-yr avg 26%
Owner-earnings margin 17% 5-yr avg 19%
Free cash flow margin 14% 5-yr avg 13%

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

What it is
Revenue is Proprietary Products (81%) and Contract-Manufactured Products (19%).
What moves the needle
Gross margin has run about 35% and operating margin about 19% through the cycle, a solid spread between what it charges and what the product costs to make. Capital spending runs about 8.9% of sales, well above depreciation, so the return earned on what it sinks into that plant weighs as much as the margin. Read this kind of business on the installed base and what follows it. On its own account, the filing leans hardest on customer concentration, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has run in the teens (median 19%, above 15% in 8 of 10 years). Owner earnings agree: roughly 17% of revenue reaches owners as cash, consistently. Returns like these are solid but short of clear franchise economics; whether they hold is what the 10-K settles, not the multiple.

Every line is arithmetic on the company's filings, shown in full in the sections below.

Where the money comes from

read the 10-K →

Proprietary Products is 81% of revenue, with Contract-Manufactured Products the other meaningful segment at 19%.

Revenue by reportable segment, FY2025
  • Proprietary Products81%$2.5B
  • Contract-Manufactured Products19%$582M
By geographyUnited States43%Other Europe Countries15%Germany12%Other11%Ireland11%France7%

From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2016–2025

realized figures from each filing · older years to the left
2016’162017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMMar 2026
Income statement
$1.5B$1.6B$1.7B$1.8B$2.1B$2.8B$2.9B$2.9B$2.9B$3.1B$3.2BRevenueRevenue
33%32%32%33%36%42%39%38%35%36%36%Gross marginGross mgn
16%15%15%15%14%13%11%12%12%13%13%SG&A / revenueSG&A/rev
2%2%2%2%2%2%2%2%2%2%2%R&D / revenueR&D/rev
$195M$226M$240M$297M$407M$752M$734M$676M$570M$585M$655MOperating incomeOp. inc.
12.9%14.1%14.0%16.1%19.0%26.6%25.4%22.9%19.7%19.0%20.3%Operating marginOp. mgn
$144M$151M$207M$242M$346M$662M$586M$593M$493M$494M$543MNet incomeNet inc.
27%35%17%20%17%14%16%17%18%20%21%Effective tax rateTax rate
Cash flow & returns
$219M$263M$289M$367M$473M$584M$724M$777M$653M$755M$715MOperating cash flowOp. cash
$91M$97M$104M$103M$109M$122M$121M$137M$155M$171M$177MDepreciationDeprec.
($34M)($200K)($38M)($2M)($17M)($238M)($6M)$23M($13M)$66M($33M)Working capital & otherWC & other
$170M$131M$105M$126M$174M$253M$285M$362M$377M$286M$257MCapexCapex
11.3%8.2%6.1%6.9%8.1%8.9%9.9%12.3%13.0%9.3%8.0%Capex / revenueCapex/rev
$129M$167M$184M$241M$363M$462M$603M$639M$498M$583M$539MOwner earningsOwner earn.
8.5%10.4%10.7%13.1%16.9%16.3%20.9%21.7%17.2%19.0%16.7%Owner earnings marginOE mgn
$49M$133M$184M$241M$298M$331M$439M$415M$276M$469M$458MFree cash flowFCF
3.3%8.3%10.7%13.1%13.9%11.7%15.2%14.1%9.6%15.3%14.2%Free cash flow marginFCF mgn
$0$0$19M$0$2M$0$0$0AcquisitionsAcquis.
$36M$39M$42M$45M$48M$51M$54M$57M$59M$61M$62MDividends paidDiv. paid
$52M$74M$71M$83M$116M$137M$203M$438M$561M$134MBuybacksBuybacks
12%12%16%17%23%35%31%25%19%18%19%ROICROIC
13%12%15%15%19%28%22%21%18%16%18%Return on equityROE
10%9%12%12%16%26%20%19%16%14%16%Retained to equityRetained/eq
Balance sheet
$203M$236M$337M$439M$616M$763M$894M$854M$485M$791M$530MCash & investmentsCash+inv
$201M$253M$288M$319M$385M$489M$507M$512M$553M$574M$686MReceivablesReceiv.
$199M$215M$215M$236M$321M$378M$415M$435M$377M$444M$453MInventoryInvent.
$122M$138M$130M$157M$213M$232M$215M$242M$239M$254M$252MAccounts payablePayables
$278M$330M$372M$398M$494M$635M$707M$704M$690M$765M$886MOperating working capitalOper. WC
$642M$744M$894M$1.1B$1.4B$1.7B$1.9B$1.9B$1.5B$2.0B$1.8BCurrent assetsCur. assets
$241M$280M$284M$342M$503M$594M$519M$672M$550M$655M$674MCurrent liabilitiesCur. liab.
2.7×2.7×3.2×3.1×2.7×2.9×3.7×2.9×2.8×3.0×2.7×Current ratioCurr. ratio
$103M$108M$106M$108M$111M$110M$107M$109M$106M$110M$109MGoodwillGoodwill
$1.7B$1.9B$2.0B$2.3B$2.8B$3.3B$3.6B$3.8B$3.6B$4.3B$4.1BTotal assetsAssets
$229M$197M$196M$257M$255M$253M$209M$207M$203M$203M$203MTotal debtDebt
$26M($39M)($141M)($182M)($360M)($510M)($685M)($647M)($282M)($589M)($327M)Net debt / (cash)Net debt
24.1×28.9×28.6×34.9×49.6×91.7×92.9×75.1×190.0×1169.8×327.5×Interest coverageInt. cov.
$1.1B$1.3B$1.4B$1.6B$1.9B$2.3B$2.7B$2.9B$2.7B$3.2B$3.0BShareholders’ equityEquity
1.3%1.0%0.9%1.3%1.6%1.3%0.8%0.8%0.6%0.8%0.9%Stock comp / revenueSBC/rev
$100K$500K$500KGoodwill written downGW imp.
Per share
75.0M75.8M75.4M75.4M75.8M76.3M75.8M75.3M73.7M72.7M72.4MShares out (diluted)Shares
$20.12$21.10$22.78$24.40$28.32$37.11$38.09$39.17$39.26$42.28$44.49Revenue / shareRev/sh
$1.91$1.99$2.74$3.21$4.57$8.67$7.73$7.88$6.69$6.79$7.50EPS (diluted)EPS
$1.72$2.20$2.44$3.19$4.79$6.05$7.96$8.49$6.76$8.02$7.44Owner earnings / shareOE/sh
$0.66$1.75$2.44$3.19$3.93$4.33$5.80$5.50$3.75$6.45$6.33Free cash flow / shareFCF/sh
$0.48$0.52$0.56$0.60$0.63$0.67$0.71$0.76$0.80$0.84$0.85Dividends / shareDiv/sh
$2.27$1.73$1.39$1.68$2.30$3.32$3.75$4.81$5.12$3.93$3.55Cap. spending / shareCapex/sh
$14.90$16.89$18.52$20.86$24.47$30.61$35.42$38.26$36.39$43.69$41.30Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+8.6%/yr+8.3%/yr
Owner earnings / share+18.7%/yr+10.9%/yr
EPS+15.1%/yr+8.3%/yr
Dividends / share+6.5%/yr+5.8%/yr
Capital spending / share+6.3%/yr+11.3%/yr
Book value / share+12.7%/yr+12.3%/yr

The record, charted

FY2016–2025

Each measure over its full record; the current point and the worst year marked.

Share count
73Mpeak FY2021
ROIC
18%low FY2017
Gross margin
36%low FY2018

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

$583Mowner earningsvs.$494Mnet incomelow FY2016

Where the cash went

ReinvestBuybacksDividendsAcquisitionsRetainedBeyond op. cash

Each year's outlays against its operating cash: the mix, and how it drifts. The hatched cap is spending beyond that year's operating cash — financed from the balance sheet or borrowing, not operations.

FY2016FY2025

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business earned $583M of owner earnings, the operating cash left after the $171M it takes just to hold its position. It put $115M more into growth; free cash flow, after that spending, was $469M.

Reported net income$494M
Owner earnings$583M · 19% of revenue
FY2025FY2024FY2023FY2022FY2021
Reported net income$494M$493M$593M$586M$662M
Depreciation & amortizationnon-cash charge added back+$171M+$155M+$137M+$121M+$122M
Stock-based compensationreal costnon-cash, but a real cost+$24M+$19M+$23M+$24M+$38M
Working capital & othertiming of cash in and out, other non-cash items+$66M−$13M+$23M−$6M−$238M
Cash from operations$755M$653M$777M$724M$584M
Maintenance capital expenditurethe spending needed just to hold position and volume−$171M−$155M−$137M−$121M−$122M
Owner earnings$583M$498M$639M$603M$462M
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−$115M−$222M−$225M−$164M−$131M
Free cash flow$469M$276M$415M$439M$331M
Owner-earnings marginowner earnings ÷ revenue19%17%22%21%16%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the maintenance capital it must spend to hold its position (here about $171M, roughly its depreciation, the rate its assets wear out). The other $115M of its capital spending is growth it chose, not upkeep it owed; charged only with the maintenance it must do, the business earns well more than the year's free cash flow shows. The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $24M), owner earnings is nearer $560M.

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • Comfortable
    Operating income $585M ÷ interest expense $500K
    What this means

    Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.

  • Net cash
    Cash $791M + ST investments $8M − debt $203M
    What this means

    Cash and short-term investments exceed every dollar of debt by $596M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Long (60+ days)
    DSO 68 + DIO 82 − DPO 47 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.

Is it a good business?

  • High through the cycle
    10-yr median, range 12%–35%; 18% latest = NOPAT $469M ÷ invested capital $2.6B
    Industry peers: median 6%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran 18% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • High through the cycle
    10-yr median margin, range 9%–22%; latest $583M = operating cash $755M − maintenance capex $171M
    Industry peers: median 7%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 19% of revenue this year, a 16% median across 10 years. It chose to put $115M more into growth, so free cash flow this year was $469M — the gap is investment, not weakness. Treating stock comp as the real expense it is (less $24M of SBC) leaves $560M.

  • Cash-backed
    Cash from ops $755M ÷ net income $494M
    What this means

    How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.

How is the cash used?

  • Reinvests most of it
    Dividends + buybacks $195M ÷ Owner Earnings $583M
    What this means

    Of $583M Owner Earnings, $195M (33%) went back to shareholders, $61M dividends, $134M buybacks. Net of $24M stock comp, the real buyback was about $110M. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.

  • Investing or harvesting? 1.67×
    Expanding
    Capex $286M ÷ depreciation $171M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 6 of 6 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Pass
    Revenue ≥ $2B · $3.1B
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 3.02×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $203M vs $1.3B WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Pass
    A profit every year (10-yr record) · no losses
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Pass
    Uninterrupted dividends · paid every year (10)
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth Pass
    Earnings +33% over the record · +215%
    What this means

    At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $7.45/share (latest year $6.99), the averaged base the calculator's gate runs on, and book value is $44.96/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2016–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 10 of 10
    What this means

    Never lost money over the record, the earnings stability Graham insisted on.

  • Return on capital ≥ 15% 8 of 10 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin 14% → 21% (3-yr avg ends)

    In the filing’s words The words confirm the number: the filing says price increases held their volume, and the margin widened with them — Buffett’s strongest mark of pricing power.

    What this means

    Through the cycle the operating margin widened — about 14% early to 21% lately, median 19% — pricing power intact or improving.

  • Reinvestment, incremental ROIC 28%
    What this means

    Every extra dollar the business reinvested came back at a high incremental return — the lens GBM read for a moat that reinvests rather than merely harvests. The record and the 10-K are where you check whether the rate holds.

  • Owner earnings growth +16%/yr
    What this means

    Owner earnings grew about 16% a year over the record.

  • Worst year 2016 · 12.9% op. margin
    What this means

    Stayed profitable even in its hardest year, the resilience that survives recessions.

  • Share count −0.3%/yr
    What this means

    Roughly flat share count, little dilution, little buyback.

  • Dividend record rising
    What this means

    Paid and raised the dividend across the record, the continuity Graham prized.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Mar 31, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$1.8B
  • Cash & short-term investments$530M
  • Receivables$686M
  • Inventory$453M
  • Other current assets$159M
Current liabilities$674M
  • Accounts payable$252M
  • Other current liabilities$422M
Current ratio2.71×all current assets ÷ what's due · Graham looked for 2×
Quick ratio2.04×stricter: inventory excluded
Cash ratio0.79×strictest: cash alone against what's due
Working capital$1.2Bthe cushion left after near-term bills
Revenue, latest quarter vs. a year ago+21.0%the freshest read on whether the business is still growing
Current ratio, recent quarters2.3× → 2.7×
Deeper floors
Tangible book value$2.9Bequity stripped of goodwill & intangibles
Net current asset value$707MGraham's net-net: current assets less all liabilities
Debt incl. operating leases$316M$113M of it operating leases
Deferred revenue$63Mcustomer cash collected before delivery; operating float

From the company's latest filing.

How the cash was used, 2016–2025

Over the record, the business generated $5.1B of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.

  • Reinvested$2.3B · 44%
  • Dividends$493M · 10%
  • Buybacks$1.9B · 37%
  • Retained (debt / cash)$473M · 9%
  • Returned to owners$2.4B

    61% of the owner earnings the business produced over the span, $493M as dividends and $1.9B as buybacks.

  • Average price paid for buybacks$225.05

    Across the years where the filing reports a share count, 8M shares were bought for $1.9B, about $225.05 each. Year to year the price paid ranged from $74.57 (2016) to $360.00 (2022); its heaviest year, 2024, paid $354.32 ($561M).

  • Net change in share count−3.5%

    The diluted count fell from 75M to 72M, so the buybacks outran the stock issued to staff.

  • Dividend record$0.84/sh

    Paid in 10 of the years on record, the per-share dividend growing about 7% a year. It was never cut over the span.

  • Return on what it retained27%

    Of the earnings it kept rather than paid out ($1.6B over the span), annual owner earnings (first three years vs last three) grew $414M, so each retained $1 added about 0.27 of yearly owner earnings. Buffett's test, run on owner earnings instead of market value.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Owner earnings
2021Eric M. Green$9.5M$35.1M$462M
2022Eric M. Green$7.9M−$12.1M$603M
2023Eric M. Green$9.4M$17.0M$639M
2024Eric M. Green$8.4M$5.3M$498M
2025Eric M. Green$7.2M$4.1M$583M

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.

  • Stock-based compensation$24M

    The slice of the business handed to employees in shares this year, 1% of revenue, equal to 4% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

Inverting the record

Invert: instead of why West Pharmaceutical is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2016–2025.

2 of the 6 tests turned up something to look into; the other 4 came back clean.

  • Look hereDid receivables and inventory outpace sales?26% → 35% of sales

    Receivables and inventory grew from $400M to $1.1B while revenue grew 113%: working capital is climbing faster than sales (26% of revenue then, 35% now). That can mean customers paying slower, stock building up, or revenue pulled forward. The filing's cash-flow and receivables notes say which.

  • Look hereAre "one-time" charges a yearly habit?8 of 10 years

    Management took an impairment or write-down in 8 of the last 10 years, $61M in all. A charge taken almost every year is not one-time; it is the business — past deals coming due, and an admission the assets were worth less than what was paid. Munger's rule: when the "one-time" keeps happening, it is the business. Read it beside the goodwill the company still carries.

And these came back clean
  • Is it less profitable than it was?
  • Did the share count rise anyway?
  • Did debt outgrow the business?
  • Did reported profit become cash?

Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.

What an owner would ask, FY2025

read the 10-K →
  • How much of the revenue rides on one buyer?
    ≈$1.5B · 48% of revenue on the largest customers (TTM)
    “Our ten largest customers accounted for 47.6% of our consolidated net sales in 2025, and one of these customers individually accounted for more than 10% of consolidated net sales, at 15.8% or $485.9 million, contributing to net sales in both the Proprietary and Contract Manufacturing reporting segme…”verify →
  • Which reported numbers are a judgment call?
    Management names Pension & retirement, Income taxes as critical estimates

    each rests partly on management's judgment; the filing's note sets out the assumptionsverify →

The questions the record and the charts do not answer on their own; each carries the figure and the place to look.

Peers, Medical Devices & Equipment

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
BAXBaxter International Inc.$11.2B40%9.2%6%10%
SOLVSolventum Corporation$8.3B20.7%12%14%
WSTWest Pharmaceutical$3.1B35%19.0%19%17%
ENOVEnovis Corporation$2.2B55%-4.4%-1%1%
ICUIICU Medical$2.2B37%2.0%5%5%
MSAMSA Safety Incorporated$1.9B45%13.2%13%11%
ITGRInteger Holdings$1.9B27%11.2%6%7%
MMSIMerit Medical Systems$1.5B45%6.2%4%7%
Group median40%10.2%6%9%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what West Pharmaceutical has delivered.

$

Through the cycle, West Pharmaceutical earns about $511M on its 16.6% median owner-earnings margin. This year’s 19.0% margin runs in line with that. Normalize, below, values the price on that through-cycle figure rather than the latest year.

Base

The assumptions

9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth · ’21→’25+0%/yr
Owner-earnings growth · ’16→’25+17%/yr
Owner-earnings yield
P/E (3-yr earnings ’23–’25)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Free cash flow $458M on 71M shares outstanding, per the 10-Q cover, as of 2026-04-20; net cash $327M. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. Capex ($257M) runs well above depreciation ($177M), so this is a build-out; Steady-state swaps total capex for maintenance (≈ depreciation), lifting the base to about $544M, the cash it would throw off if it stopped expanding. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "West Pharmaceutical (WST), the owner's record," https://ownerscorecard.com/c/WST, data as of 2026-07-09.

Manual order: ← WSR its page in the Manual WT →

Industry order: ← WRBY the Medical Devices & Equipment chapter XRAY →